Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017-08-10
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).
Abstract
Purpose Docetaxel and cyclophosphamide (TC) was superior to doxorubicin and cyclophosphamide (AC) in a trial in early breast cancer. However, activity of TC relative to AC regimens with a taxane (TaxAC) is unknown. Methods In a series of three adjuvant trials, women were randomly assigned to TC for six cycles (TC6) or to a standard TaxAC regimen. US Oncology Research (USOR) 06-090 compared TC6 with docetaxel, doxorubicin, and cyclophosphamide (TAC6). National Surgical Adjuvant Breast and Bowel Project (NSABP) B-46-I/USOR 07132 compared TC6, TAC6, or TC6 plus bevacizumab. NSABP B-49 compared TC6 with several standard AC and taxane combination regimens. Before any analysis of individual trials, a joint efficacy analysis of TC versus the TaxAC regimens was planned, with invasive disease-free survival (IDFS) as the primary end point. Patients who received TC6 plus bevacizumab on NSABP B-46-I/USOR 07132 were not included. A hazard ratio (HR) from a stratified Cox model that exceeded 1.18 for TC6 versus TaxAC was predefined as inferiority for TC6. The prespecified interim monitoring plan was to report for futility if the HR was > 1.18 when 334 IDFS events were observed (50% of 668 events required for definitive analysis). Results A total of 2,125 patients were randomly assigned to receive TC6 regimens and 2,117 patients were randomly assigned to receive TaxAC regimens. The median follow-up time was 3.3 years. There were 334 IDFS events, and the HR for TC6 versus TaxAC was 1.202 (95% CI, 0.97 to 1.49), which triggered early reporting for futility. The 4-year IDFS was 88.2% for TC6 and was 90.7% for TaxAC ( P = .04). Tests for treatment interaction by protocol, hormone receptor status, and nodal status were negative. Conclusion The TaxAC regimens improved IDFS in patients with high-risk human epidermal growth factor receptor 2-negative breast cancer compared with the TC6 regimen.
Related Questions
Which chemotherapy is preferred between TC and AC-T in a young patient with ER+/PR+/HER2- node negative breast cancer, intermediate grade, with high OncoType score?
If this patient has a small, node negative, hormone receptor positive, HER2 negative intermediate grade tumor, I would be comfortable with recommending 4 cycles of adjuvant docetaxel and cyclophosphamide. Based on ABC trial results, the groups that benefited from AC-T regimen were patients with high...
How do you interpret the EBCTCG meta-analysis analyzing the magnitude of benefit of anthracyclines in early stage ER+ breast cancer?
The appreciation of studies testing the specific benefit of adding or substituting anthracyclines as adjuvant therapy for early stage breast cancer requires a historical overview (so my apologies for a very long response….). Several of the earlier trials comparing non-anthracycline therapies (primar...
Would you consider administration of neoadjuvant anthracycline for cT2N1 ER+/PR+/HER2- patients given that this may be excessive for N1 disease, or do you wait until nodal status is confirmed on surgical pathology?
Yes, I would consider anthracycline-based therapy in cT2N1M0 HR+/HER2-negative breast cancer. The ABC trial, the only large-scale trial testing anthracycline specifically in HER-negative cases, showed only a marginal benefit in disease-free survival (not quite statistically significant), and appeare...
Does the magnitude of OncoType recurrence score above 26 inform decision between TC and AC/T in ER+ HER2- 1-3 node positive, postmenopausal patients with breast cancer?
We don't have any evidence for correlating recurrence score with choice of chemotherapy. Based on RxPONDER, we know that patients with 1-3 positive lymph nodes and scores less than 25, do not benefit from chemotherapy. Based on retrospective data, we have enough evidence that scores more than 30 wou...
How would you approach treatment for a pre-menopausal patient with PR-positive, ER-negative, HER2-negative cT1c N1 breast cancer?
The prevalence of ER- PR+ HER2- breast cancer is relatively low and probably ranges from about 0-8%, with concerns about technical errors in HR status determination by IHC often being expressed in this instance. Because of this, I would consider repeat receptor testing at some point (an additional b...
What adjuvant chemotherapy regimen do you recommend for a patient with T1cN0 TNBC?
This is such a nuanced question that comes up with our fellows and affiliates a lot. I will give my take on this, although I want to acknowledge there are still pockets of uncertainty here!I want to start by saying that in the purely adjuvant setting, we have the ABC trials (USOR 06-090, NSABP-B46I/...
What adjuvant chemotherapy would you recommend in a premenopausal patient with pT1cN1 HR+ breast cancer who previously received an anthracycline and cyclophosphamide 30 years prior?
I would defer anthracycline regimens since the risk of cardiomyopathy increases after cumulative dose doxorubicin exceeds 400-450 mg/m2. Her prior exposure to alkylating agents also puts her at risk for secondary MDS from cyclophosphamide which is pretty much present in all modern chemotherapy regim...
For anatomic stage III ER/PR+ breast cancer treated upfront with surgery, how do you decide which adjuvant chemotherapy to offer?
Anatomic stage III breast cancer includes different clinical scenarios ranging from a tumor over 5cm with 1-3 + lymph nodes, tumors with 4 or more + lymph nodes, tumors with chest wall/skin invasion, and inflammatory breast cancer. For the first scenario, a T3N1 post menopausal female with an Oncoty...
What is your neoadjuvant chemotherapy of choice in patients with ER+ breast CA who are receiving neoadjuvant therapy with goal to convert to BCS from mastectomy?
I have tried to use Dose dense doxorubicin and cyclophosphamide followed by dose dense paclitaxel (AC-T) in most situations in the neoadjuvant setting since lymph node status is not known definitively prior to surgery. There is adjuvant data from the ABC trial for non inferiority of docetaxel and cy...
What would be your regimen of choice for a healthy 80+ year old with localized triple negative breast cancer?
My inclination would be to avoid administering an anthracycline to such a patient, as long as you include a taxane and carboplatin in her treatment regimen. If you're treating her in the neoadjuvant setting, Sharma and colleagues achieved a similar pCR rate with every 3-week docetaxel and carboplati...
Would you treat an ER/PR+ inflammatory breast cancer that is HER2 2+ by IHC but 5% positive by FISH as HER2 positive?
Yes, because it is inflammatory breast cancer and the standard of care is to include neoadjuvant chemotherapy anyway. In this case, I'd use neoadjuvant TCHP and then retest breast biomarkers at surgery (MRM, with ALND, is standard surgery for inflammatory breast cancer at this time) to see if there ...
How do you determine whether to choose a non-anthracycline neoadjuvant chemotherapy regimen in a fit patient with TNBC?
Optimal neoadjuvant chemotherapy (NAC) regimen for TNBC has not been established and treatment regimens are usually mirrored from adjuvant trials. When choosing neoadjuvant chemotherapy regimen, the goal should be to achieve pathological complete response (pCR), since patients who do not achieve a p...
Is there any role for using Oncotype Dx to decide between neoadjuvant chemotherapy vs. endocrine therapy in a postmenopausal woman with T2N0 ER+,HER2- breast cancer?
Typically, my decision for NAC is motivated by the following where I'm convinced that there is enough risk that I will give a particular regimen: 1) NAC will help determine later therapy (e.g. triple ngtv and adj capecitabine OR HER2+ and TDM-1) and/or 2) NAC will assist with surgical approach (e.g....
What is the most appropriate adjuvant chemotherapy regimen for pre-menopausal, pT1bN0, TNBC?
In my opinion for T1bN0 TNBC tumors TCx4 is sufficient. In the ABC trials the absolute difference in N0 TNBC between the TCx6 and TaxAC arms was only 2.5%. This included larger tumors over 1 cm. A retrospective study in 1151 TNBC T1cN0 patients found a benefit for adjuvant chemotherapy in T1c patien...
Would you finish neoadjuvant TC in a postmenopausal stage I TNBC patient who transferred care to your practice after 1 cycle or would you proceed with surgery and finish chemo adjuvantly?
Since I often administer TC x 4 in the adjuvant setting to patients with stage I TNBC, I would definitely be comfortable continuing this regimen in the neoadjuvant setting in such a patient. I use TC in these patients based on results from the ABC analysis (Blum et al, JCO 2017) which demonstrated a...
Why do we give four cycles of TC as adjuvant therapy when some of the clinical trials administered six cycles?
There are three trials I use to think about this issue: USOR 9735 (TC x 4 vs AC x 4, Jones et al JCO 2009; 27: 1177-1183), ECOG 1199 (AC x 4 with paclitaxel qw x 12, vs taxol q3w x 4, vs docetaxel qw x 12, vs docetaxel q3w x 4, Sparano et al JCO 2015; 33: 2353-2360) and the ABC analysis (TC x 6 vs T...
Would you consider age of 70 years as a contraindication (without any other cardiac risks) to use anthracycline in a triple negative breast cancer patient?
As always, it depends. The DFS advantage for anthracycline-based regimens over TCx6 in the ABC trials (J Clin Oncol 35:2647, 2017) was for patients with lymph node involvement, so they were at high risk. In a fit woman who is age 70 or older, the benefits of including the anthracycline likely outwei...
Would you give adjuvant chemotherapy to a post-menopausal woman with strongly ER/PR positive locally advanced lobular carcinoma with >3 axillary LNs?
The total body of evidence for the 21-gene assay in the setting of 1-3 LNs is supportive of the current NCCN guidelines, which suggest considering that patients with ER+ disease, one to three positive nodes, and low RS can avoid adjuvant chemotherapy and receive endocrine therapy alone, on the ba...
Do you have a certain tumor size threshold in which you change chemotherapy recommendations for a small, triple negative breast cancer?
Breast cancer death from small tumors is often underestimated. In 2000, 0.92%, 4.0%, and 10.7% breast cancer-specific deaths were due to T1a, T1b, and T1c node-negative cancers, respectively, which increased significantly to 1.9%, 5.8%, and 14.7% by 2017. This is an interesting read on death from sm...
When do you choose a non-anthracycline containing regimen, such as docetaxel/cyclophosphamide, for patients with hormone receptor positive, HER2 negative breast cancer who warrant adjuvant chemotherapy?
As in many of the decisions we face, we need to balance benefit and risk. Based on the ABC suite of trials, anthracycline regimens are slightly more effective than non-anthracycline (taxane only) regimens. To be clear, the ABC data is far from perfect - the trial design changed at least 3 times duri...